Thrombolysis and Acute Stroke Treatment (TAST) 2011: Forward to Acute Stroke Tre

描述（由申请人提供）：继之前十次关于急性缺血性卒中溶栓治疗主题的国际专题讨论会之后，纽约科学院（NYAS）主办了该系列的第11次会议：溶栓和急性卒中治疗（TAST） 2011：展望2021年急性卒中治疗。由博士组织。del Zoppo（该基金的PI和本系列的联合创始人）和科学委员会的Alexandrov博士。Marler， Mori和Kaste，以及一个国际顾问委员会，这个为期三天的会议将于2011年12月1-3日在纽约NYAS会议中心举行。研讨会的目标是：(i)提供一个中立的论坛，a)就缺血性卒中急性治疗的研究和临床实践的最新和未来方向进行具有挑衅性和前瞻性的讨论，以及b)更好地了解未来十年中风研究和患者的前景；（ii）突出在该领域工作的年轻研究者的研究贡献；（iii）开发高质量的印刷和电子持久材料，向全球科学界报告会议的介绍。该计划将包括主题演讲和定向全体演讲，两个小型专题讨论会和一个实践研讨会，并包括大量的网络时间，听众和小组讨论。这将导致有力的相互作用。演讲者将被明确要求在他们的演讲中回答一系列问题，以促进数据驱动，多学科和重点思想的产生，探索缺血性中风作为与其他疾病实体相关的全身性疾病，并更好地解决脑损伤的演变。重点主题包括：(i)神经血管单元及其损伤；（ii）目前用于或正在开发的用于急性卒中治疗的溶栓药物的安全性和有效性；（iii）对半影的新看法；（iv）考虑时间窗口和优化交付条件；(v)稳定脑组织以帮助患者康复；（vi）提高纤溶酶原激活剂的安全性；（七）影响风险和利益的因素；（viii）替代方法。我们期待来自世界范围内脑血管疾病直接领域内外的广泛参与（250-300名与会者），从基础研究到临床环境。将从提交的摘要中选出的海报和简短介绍纳入议程，并提供折扣注册费和旅行研究金，将鼓励少数民族和青年研究人员参与。该系列在美国的前两次会议分别在拉霍亚（1992年）和贝塞斯达（1998年）举行，分别由斯克里普斯诊所和研究基金会和NINDS/辛辛那提大学承办。鉴于这些成功，及时和相关的主题，以及我们的组织者和顾问的科学严密性，我们期待有大量的人来见证这些现场和持久的讨论，这将促进跨学科合作，以促进改进的治疗管理，新的研究思路和方向，以及未来缺血性中风急性治疗的指导方针。

DESCRIPTION (provided by applicant): Following ten previous international symposia on the theme of thrombolytic treatment of acute ischemic stroke, The New York Academy of Sciences (NYAS) is hosting the 11th meeting in this series: Thrombolysis and Acute Stroke Treatment (TAST) 2011: Forward to Acute Stroke Treatment in 2021. Organized by Drs. del Zoppo (PI of this grant and co-founder of this series) and Alexandrov, the Scientific Committee, Drs. Marler, Mori, and Kaste, and an International Advisory Board, this three-day conference will be held at NYAS Conference Center in New York, on 1-3 December, 2011. The goals of the symposium are to: (i) provide a neutral forum to a) generate provocative and forward-looking discussions about the state-of-the-art and future directions of research and clinical practice in the acute treatment of ischemic stroke, and b) better understand what the future holds for stroke research and patients ten years for now; (ii) highlight the research contributions of young investigators working in this field; and (iii) develop high-quality print and electronic enduring materials reporting the meeting presentations to the global scientific community. The program will feature keynote and directed plenary lectures, two mini-symposia, and a hands-on workshop, and incorporate plenty of time for networking, and audience and panel discussions. These will lead to vigorous interactions. Speakers will be explicitly asked to respond to a set of questions during their presentations to foster the generation of data-driven, multidisciplinary and focused ideas, explore ischemic stroke as a systemic disease related to other disease entities, and better address the evolution of the brain injury. Highlighted topics include: (i) the neurovascular unit and its injury; (ii) the safety and efficacy of thrombolytic agents currently used or being developed for acute stroke treatment; (iii) new views of the penumbra; (iv) time window considerations and optimized delivery conditions; (v) stabilization of brain tissue for patient recovery; (vi) enhancing the safety of plasminogen activators; (vii) factors that influence risk and benefit; and (viii) alternative approaches. We anticipate wide participation (250-300 attendees) from within and outside the immediate area of cerebrovascular disease, from basic research to clinical settings worldwide. The incorporation of poster and short presentations selected from submitted abstracts into the agenda, and the availability of discounted registration prices and travel fellowships will encourage participation from minority and young investigators. Previous meetings in the US in this series have occurred in La Jolla (1992) and Bethesda (1998), undertaken by the Scripps Clinic and Research Foundation and by the NINDS/ University of Cincinnati, respectively. Given the success in those, the timely and relevant topic, and the scientific rigor of our organizers and advisors, we anticipate a strong turnout to witness these live and enduring discussions, which will foster cross-disciplinary collaborations to promote improved treatment management, new research ideas and directions, and future guidelines for acute treatments of ischemic stroke. PUBLIC HEALTH RELEVANCE: A three-day, scientific conference at the New York Academy of Sciences will provide a neutral forum for clinicians and scientists, experts in cerebrovascular disease and related disorders, to generate provocative and forward-looking discussions to better articulate how clinical and basic science can advance blood flow restorative treatments and medical support in the coming ten to fifteen years, to promote and improve acute treatment of ischemic stroke. The program's cross-disciplinary discussions will approach ischemic stroke as a systemic disease, recognizing the contributions of hypertension, diabetes, and disorders of aging, beyond the conventional targets of time from symptoms onset to deeper understanding of basic mechanisms and the advanced science of clinical trials. This forum will also generate enduring print and online publications to highlight these discussions and make them available to the global scientific community and the general public, foster cross-disciplinary dialogue and collaborations, and promote attention toward the future medical care of stroke patients. 1